NEW HAVEN, Conn., Oct. 11, 2018 — BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology, announced today that its Chief Executive Officer, Dr. Vimal Mehta, will present at the 2018 BIO Investor Forum, being held October 17-18, 2018 at the Westin St. Francis Hotel in San Francisco, California.
|Conference Presentation Details:|
|Date:||Wednesday, October 17, 2018|
|Time:||10:45 AM PDT|
A live webcast of the presentation will be accessible through the Investors section of the Company’s website at www.bioxceltherapeutics.com and will be available for 30 days following the event.
About BioXcel Therapeutics, Inc.: BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The Company’s two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. For more information, please visit www.bioxceltherapeutics.com.